United States

AFFO (TTM)

AFFO/share (TTM)

AFFO/share Guidance

AFFO (Quarter)

AFFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/AFFO

Size (ft²)

Occupancy

The Company is a fully integrated REIT primarily focused on the ownership, acquisition, development and management of
retail properties net leased to industry leading tenants.

Agree Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, ADC is classified as investment grade

Period: 2022 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2022 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's Adjusted FFO

Adjusted FFO Growth

Assessment of recent increases in Adjusted FFO per share, indicating profitability

Adjusted FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Realty Income (O -0.56%) and Agree Realty (ADC 0.20%) are competitors in the net lease niche of real estate investment trust (REIT) arena. Realty Income is still down around 25% from its pre-coronavirus pandemic highs, while Agree Realty has rallied back some and is now just 10% below its peak.

Best Stock to Buy Right Now: Realty Income vs. Agree Realty

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that Kirk Klatt has joined the Company as Vice President of Leasing. Mr. Klatt will be responsible for leading the Company's leasing function and management of key retailer relationships. Mr. Klatt has over 20 years of real estate leasing, acquisition, and operational experience. Previously, he served as Senior Vice President of Real Estate at NETSTREIT Corp. (NYSE: NTST), where he spent appr.

Agree Realty Announces the Addition of Kirk Klatt as Vice President of Leasing

First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the BL-B01D1-101 (CN), BL-B01D1-203 (CN), and BL-B01D1-LUNG-101 (U.S.,/EU) studies REDMOND, Wash. and PRINCETON, N.J.

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in lung cancer at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC25). Data at WCLC will showcase the company's progress towards creating new standards of care for patients with lung cancer, including a late-breaking oral presentation featuring the primary analy.

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer at WCLC

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.256 per common share. The monthly dividend reflects an annualized dividend amount of $3.072 per common share, representing a 2.4% increase over the annualized dividend amount of $3.00 per common share from the third quarter of 2024. The dividend is payable September 15, 2025 to stockholders.

Agree Realty Declares Monthly Common and Preferred Dividends

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that Fitch Ratings (“Fitch”) has assigned the Company an A- issuer rating with a stable outlook. According to Fitch's press release, the A- issuer rating reflects the Company's superior tenant credit quality with a focus on investment grade tenants as well as tenants whose products are less exposed to e-commerce or who have successfully adapted omnichannel strategies. In addition, Fitch noted.

Agree Realty Achieves A- Credit Rating From Fitch Ratings

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients Expansion to 100 r/r DLBCL patients underway in LOTIS-7 Phase 1b trial; Additional data to be shared in second half of 2025 LOTIS-5 Phase 3 trial expected to reach prespecified progression-free survival (PFS) events by end of 2025; update to follow once data are available Completed $100 million private placement extending expected cash runway into 2028 LAUSANNE, Switzerland , Aug. 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the second quarter ended June 30, 2025, and provided operational updates. "Entering the second half of 2025, we have streamlined our strategic focus and strengthened our financial foundation, which now allows us to pursue multiple promising opportunities to expand ZYNLONTA® into earlier lines of therapy in DLBCL and indolent lymphomas," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

While the December 2024 interest rate cut of 25 basis points may be the last until at least September, it is an excellent bet that the federal funds rate will be lower than today's effective rate of 4.23%, which is already below the long-term average of 4.61%.

Rate Cuts Could Launch These 5 Commercial REIT Stocks Much Higher

Your investment needs change when you switch from building your wealth to trying to live off of your savings. Suddenly, income is a much more important factor in the investing equation.

2 Stocks That Cut You a Check Each Month

LAUSANNE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates.

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

Real estate investment trusts (REITs) are generally income investments, but they all go about the income theme a bit differently. For example, Sun Communities (SUI 0.22%) is often viewed as a growth-oriented REIT, while a REIT like Realty Income (O 1.28%) is all about a sustainable high yield.

Better Dividend Stock: Sun Communities vs. Agree Realty

LAUSANNE, Switzerland , Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 127,000 of the Company's common shares to three new employees on August 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter ended June 30, 2025. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. Second Quarter 2025 Financial and Operating Highlights: Invested approximately $350 million in 110 retail net lease properties across all three external growth platforms Net Income per share attributable to common stockholders decreased 18.5% to $.

Agree Realty Corporation Reports Second Quarter 2025 Results

Shares of Realty Income (NYSE:O) gained 0.86% over the past month, bringing its year-to-date gain to 9.45%. In addition to outperforming the S&amp;P 500&#8217;s gain of 8.61% in 2025, O has provided shareholders with a dividend currently yielding 5.60%. Realty Income remains a staple in dividend investors&#8217; portfolios. The commercial REIT dividend — which pays out monthly and has for 659 consecutive months — is a large reason investors are confident in the stock moving forward. Another reason: its expanding footprint in the European market that has seen commercial properties with long-term net lease agreements added to its +13,000-property portfolio in the U.K., Spain and other countries. Billing itself &#8220;The Monthly Dividend Company,&#8221; the real estate investment trust (REIT) blazed a new path in the field that numerous other REITs now follow. The track record of payments for O is remarkable, and since being listed on the NYSE in 1994, the REIT has increased its dividend every quarter. Having raised the payout for 30 consecutive years, Realty Income is now a Dividend Aristocrat, or a stock that is part of the S&amp;P 500 and has increased its dividend for 25 consecutive years or more. Since its IPO in 1994, Realty Income has provided investors with a 589.46% return, not including reinvested dividends. The question is, where does Realty Income stock go from here. 24/7 Wall St. offers readers insights into our assumptions about the stock’s prospects, what sort of growth we see in O stock for the next several years, and our best estimates for Reality Income stock price each year through 2030. Realty Income (O) Recent Stock Performance Here’s a table summarizing the performance in share price, revenues, and adjusted funds from operations (AFFO) of O stock from 2019 to 2024: Year Stock Price Revenue* Adjusted Funds From Operations (AFFO)* 2019 $71.30 $1.488 $1.050 2020 $60.20 $1.647 $1.172 2021 $71.59 $2.080 $1.488 2022 $63.43 $3.343 $2.401 2023 $57.42 $4.

Realty Income (NYSE: O) Stock Price Prediction and Forecast 2025-2030 (July 2025)

Annaly Capital (NLY 0.66%) has a huge dividend yield that approaches 15%. And the mortgage real estate investment trust (REIT) just increased its dividend at the start of 2025.

Prediction: 2 Stocks That Will Be Worth More Than Annaly Capital 5 Years From Now

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that Nature Medicine (IF: 58.7) has published the results of the Phase 1 clinical study of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma[Link]. Publication in this leading international academic journal indicates the strong recognition of the therapy's clinical potential and marks another significant milestone in China's progress in developing novel anti-tumor medications.

Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

TYSONS, Va.--(BUSINESS WIRE)--Alarm.com (Nasdaq: ALRM) announces the release of its latest Smart Thermostat—the ADC-T25. Building on the proven reliability of Alarm.com's suite of thermostats, the T25 is compatible with most common HVAC systems, offering the easiest installation yet, a streamlined design, and advanced sensing capabilities, all at a market-expanding, affordable price point. Designed by Building36 with easy installation in mind, the T25 has flexible wiring options that allow it t.

Alarm.com Launches the ADC-T25 Smart Thermostat: Advanced HVAC Control at an Accessible Price

Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that its highly impactful programs on ADC and Radiopharma programs, which includes collaborations and preclinical studies on cancer therapies with Accum® are ongoing. Defence's Accum®-based ADCs have demonstrated enhanced intracellular delivery and cytotoxic activity in multiple preclinical cancer models compared to conventional ADCs.

Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer

When you shift from building a nest egg to living off of your savings in retirement, there may also be a big change in the investment approach you take. Income often becomes more important since leaving the workforce means you need to replace the monthly income stream from your job.

3 Stocks That Cut You a Check Each Month

Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.

5 Monthly Pay High-Yield Passive Income Stocks Are Printing Money For Shareholders

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.256 per common share. The monthly dividend reflects an annualized dividend amount of $3.072 per common share, representing a 2.4% increase over the annualized dividend amount of $3.00 per common share from the third quarter of 2024. The dividend is payable August 14, 2025 to stockholders of.

There are different ways to use dividends when it comes to selecting investments. Often, dividend investors focus all their attention on the highest-yielding stocks.

2 Top Dividend Stocks to Buy in July

HONG KONG , July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's first bispecific ADC to enter clinical trials.

Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy

LAUSANNE, Switzerland , July 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,000 of the Company's common shares to one new employee on July 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its second quarter 2025 operating results after the market closes on Thursday, July 31, 2025. A conference call to discuss the Company's operating results is scheduled for Friday, August 1, 2025 at 9:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (800) 715-9871   International (646) 307-1963  .

Agree Realty Announces Second Quarter 2025 Earnings Release Date and Conference Call Information

SAN FRANCISCO and SUZHOU, China , June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. This strategic focus aims to redefine the standards of cancer treatment and propel Innovent toward becoming a global, premier biopharmaceutical leader.

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda® (pembrolizumab).

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

We have to consider that insiders buying their stock wouldn't put up their own money unless they believed the move would be profitable.

Five Popular Stocks Insiders Have Been Aggressively Buying

According to the Internal Revenue Service (IRS), passive income generally includes earnings from rental activity or any trade, business, or investment in which the individual does not materially participate.

5 Very Safe Dividend Stocks Can Provide a Lifetime of Monthly Passive Income

Using Realty Income's annualized dividend of $3.228, you could collect an easy $1,400 a year.

If You Want $8,030 in Annual Income, Invest $25,000 in Each of these Stocks Today

Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Retired investors who have shifted from building a nest egg to living off their accumulated savings often start to focus on dividend stocks. Going with monthly pay dividend stocks is almost like creating your own paycheck.

​​3 Stocks That Cut You a Check Each Month

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT KIRK KLATT HAS JOINED THE COMPANY AS VICE PRESIDENT OF LEASING. MR. KLATT WILL BE RESPONSIBLE FOR LEADING THE COMPANY'S LEASING FUNCTION AND MANAGEMENT OF KEY RETAILER RELATIONSHIPS. MR. KLATT HAS OVER 20 YEARS OF REAL ESTATE LEASING, ACQUISITION, AND OPERATIONAL EXPERIENCE. PREVIOUSLY, HE SERVED AS SENIOR VICE PRESIDENT OF REAL ESTATE AT NETSTREIT CORP. (NYSE: NTST), WHERE HE SPENT APPR.

AGREE REALTY ANNOUNCES THE ADDITION OF KIRK KLATT AS VICE PRESIDENT OF LEASING

FIRST BREAKTHROUGH THERAPY DESIGNATION IN THE U.S. FORSYSTIMMUNE AND BRISTOL MYERS SQUIBB'S IZALONTAMAB BRENGITECAN (IZA-BREN) BASED ON DATA FROM THE BL-B01D1-101 (CN), BL-B01D1-203 (CN), AND BL-B01D1-LUNG-101 (U.S.,/EU) STUDIES REDMOND, WASH. AND PRINCETON, N.J.

IZALONTAMAB BRENGITECAN (EGFRXHER3 ADC) GRANTED BREAKTHROUGH THERAPY DESIGNATION BY U.S. FDA FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED EGFR-MUTATED NON-SMALL CELL LUNG CANCER

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DAIICHI SANKYO (TSE: 4568) WILL PRESENT NEW CLINICAL RESEARCH ACROSS ITS DXD ANTIBODY DRUG CONJUGATE (ADC) PORTFOLIO IN LUNG CANCER AT THE IASLC 2025 WORLD CONFERENCE ON LUNG CANCER HOSTED BY THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (#WCLC25). DATA AT WCLC WILL SHOWCASE THE COMPANY'S PROGRESS TOWARDS CREATING NEW STANDARDS OF CARE FOR PATIENTS WITH LUNG CANCER, INCLUDING A LATE-BREAKING ORAL PRESENTATION FEATURING THE PRIMARY ANALY.

DAIICHI SANKYO PRESENTS NEW DATA IN SMALL CELL LUNG CANCER AND UPDATES ACROSS ADC PORTFOLIO HIGHLIGHTING PROGRESS IN CREATING NEW STANDARDS OF CARE FOR PATIENTS WITH LUNG CANCER AT WCLC

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.256 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.072 PER COMMON SHARE, REPRESENTING A 2.4% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.00 PER COMMON SHARE FROM THE THIRD QUARTER OF 2024. THE DIVIDEND IS PAYABLE SEPTEMBER 15, 2025 TO STOCKHOLDERS.

AGREE REALTY DECLARES MONTHLY COMMON AND PREFERRED DIVIDENDS

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT FITCH RATINGS (FITCH) HAS ASSIGNED THE COMPANY AN A- ISSUER RATING WITH A STABLE OUTLOOK. ACCORDING TO FITCH'S PRESS RELEASE, THE A- ISSUER RATING REFLECTS THE COMPANY'S SUPERIOR TENANT CREDIT QUALITY WITH A FOCUS ON INVESTMENT GRADE TENANTS AS WELL AS TENANTS WHOSE PRODUCTS ARE LESS EXPOSED TO E-COMMERCE OR WHO HAVE SUCCESSFULLY ADAPTED OMNICHANNEL STRATEGIES. IN ADDITION, FITCH NOTED.

AGREE REALTY ACHIEVES A- CREDIT RATING FROM FITCH RATINGS

ZYNLONTA IN COMBINATION WITH GLOFITAMAB (COLUMVI) DEMONSTRATED OVERALL RESPONSE RATE (ORR) OF 93.3% AND A COMPLETE RESPONSE (CR) RATE OF 86.7% IN LOTIS-7 ACROSS 30 EFFICACY EVALUABLE PATIENTS EXPANSION TO 100 R/R DLBCL PATIENTS UNDERWAY IN LOTIS-7 PHASE 1B TRIAL; ADDITIONAL DATA TO BE SHARED IN SECOND HALF OF 2025 LOTIS-5 PHASE 3 TRIAL EXPECTED TO REACH PRESPECIFIED PROGRESSION-FREE SURVIVAL (PFS) EVENTS BY END OF 2025; UPDATE TO FOLLOW ONCE DATA ARE AVAILABLE COMPLETED $100 MILLION PRIVATE PLACEMENT EXTENDING EXPECTED CASH RUNWAY INTO 2028 LAUSANNE, SWITZERLAND , AUG. 12, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED OPERATIONAL UPDATES. "ENTERING THE SECOND HALF OF 2025, WE HAVE STREAMLINED OUR STRATEGIC FOCUS AND STRENGTHENED OUR FINANCIAL FOUNDATION, WHICH NOW ALLOWS US TO PURSUE MULTIPLE PROMISING OPPORTUNITIES TO EXPAND ZYNLONTA INTO EARLIER LINES OF THERAPY IN DLBCL AND INDOLENT LYMPHOMAS," SAID AMEET MALLIK, CHIEF EXECUTIVE OFFICER OF ADC THERAPEUTICS.

ADC THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

LAUSANNE, SWITZERLAND , AUG. 5, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST ON TUESDAY, AUGUST 12, 2025, AT 8:30 A.M. EDT TO REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025 AND PROVIDE OPERATIONAL UPDATES.

ADC THERAPEUTICS TO HOST SECOND QUARTER 2025 FINANCIAL RESULTS CONFERENCE CALL ON AUGUST 12, 2025

LAUSANNE, SWITZERLAND , AUG. 1, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE GRANTS OF OPTIONS TO PURCHASE AN AGGREGATE OF 127,000 OF THE COMPANY'S COMMON SHARES TO THREE NEW EMPLOYEES ON AUGUST 1, 2025 (EACH, A "GRANT"). THE GRANTS WERE OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEES' EMPLOYMENT.

ADC THERAPEUTICS MAKES GRANTS TO NEW EMPLOYEES UNDER INDUCEMENT PLAN

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED RESULTS FOR THE QUARTER ENDED JUNE 30, 2025. ALL PER SHARE AMOUNTS INCLUDED HEREIN ARE ON A DILUTED PER COMMON SHARE BASIS UNLESS OTHERWISE STATED. SECOND QUARTER 2025 FINANCIAL AND OPERATING HIGHLIGHTS: INVESTED APPROXIMATELY $350 MILLION IN 110 RETAIL NET LEASE PROPERTIES ACROSS ALL THREE EXTERNAL GROWTH PLATFORMS NET INCOME PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS DECREASED 18.5% TO $.

AGREE REALTY CORPORATION REPORTS SECOND QUARTER 2025 RESULTS

SAN FRANCISCOAND SUZHOU,CHINA, JULY 16, 2025 /PRNEWSWIRE/ -- INNOVENT BIOLOGICS, INC. ("INNOVENT") (HKEX: 01801), A WORLD-CLASS BIOPHARMACEUTICAL COMPANY THAT DEVELOPS, MANUFACTURES AND COMMERCIALIZES HIGH-QUALITY MEDICINES FOR THE TREATMENT OF ONCOLOGY, CARDIOVASCULAR AND METABOLIC, AUTOIMMUNE, OPHTHALMOLOGY AND OTHER MAJOR DISEASES, ANNOUNCED THAT NATURE MEDICINE (IF: 58.7) HAS PUBLISHED THE RESULTS OF THE PHASE 1 CLINICAL STUDY OF IBI343, AN INNOVATIVE ANTI-CLDN18.2 ADC, FOR THE TREATMENT OF ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION (G/GEJ) ADENOCARCINOMA[LINK]. PUBLICATION IN THIS LEADING INTERNATIONAL ACADEMIC JOURNAL INDICATES THE STRONG RECOGNITION OF THE THERAPY'S CLINICAL POTENTIAL AND MARKS ANOTHER SIGNIFICANT MILESTONE IN CHINA'S PROGRESS IN DEVELOPING NOVEL ANTI-TUMOR MEDICATIONS.

NATURE MEDICINE PUBLISHED PHASE 1 RESULTS OF INNOVENT BIOLOGICS' ANTI-CLDN18.2 ADC (IBI343) IN PATIENTS WITH ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

TYSONS, VA.--(BUSINESS WIRE)--ALARM.COM (NASDAQ: ALRM) ANNOUNCES THE RELEASE OF ITS LATEST SMART THERMOSTATTHE ADC-T25. BUILDING ON THE PROVEN RELIABILITY OF ALARM.COM'S SUITE OF THERMOSTATS, THE T25 IS COMPATIBLE WITH MOST COMMON HVAC SYSTEMS, OFFERING THE EASIEST INSTALLATION YET, A STREAMLINED DESIGN, AND ADVANCED SENSING CAPABILITIES, ALL AT A MARKET-EXPANDING, AFFORDABLE PRICE POINT. DESIGNED BY BUILDING36 WITH EASY INSTALLATION IN MIND, THE T25 HAS FLEXIBLE WIRING OPTIONS THAT ALLOW IT T.

ALARM.COM LAUNCHES THE ADC-T25 SMART THERMOSTAT: ADVANCED HVAC CONTROL AT AN ACCESSIBLE PRICE

MONTREAL, QUEBEC--(NEWSFILE CORP. - JULY 14, 2025) - DEFENCE THERAPEUTICS INC.(CSE: DTC) (OTCQB: DTCFF) (FSE: DTC)("DEFENCE" OR THE "COMPANY"), A LEADING BIOTECHNOLOGY COMPANY SPECIALIZING IN DRUG DELIVERY TECHNOLOGIES, IS PLEASED TO ANNOUNCE THAT ITS HIGHLY IMPACTFUL PROGRAMS ON ADC AND RADIOPHARMA PROGRAMS, WHICH INCLUDES COLLABORATIONS AND PRECLINICAL STUDIES ON CANCER THERAPIES WITH ACCUM ARE ONGOING. DEFENCE'S ACCUM-BASED ADCS HAVE DEMONSTRATED ENHANCED INTRACELLULAR DELIVERY AND CYTOTOXIC ACTIVITY IN MULTIPLE PRECLINICAL CANCER MODELS COMPARED TO CONVENTIONAL ADCS.

DEFENCE'S ACCUM TECHNOLOGY WITH ADC AND RADIOPHARMACEUTICAL PROGRAMS TARGET CANCER

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.256 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.072 PER COMMON SHARE, REPRESENTING A 2.4% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.00 PER COMMON SHARE FROM THE THIRD QUARTER OF 2024. THE DIVIDEND IS PAYABLE AUGUST 14, 2025 TO STOCKHOLDERS OF.

HONG KONG , JULY 3, 2025 /PRNEWSWIRE/ -- AKESO, INC. (9926.HK) ("AKESO" OR THE "COMPANY") HAS ANNOUNCED THE SUCCESSFUL ENROLLMENT OF THE FIRST PATIENT IN ITS PHASE IA CLINICAL TRIAL FOR AK146D1, A BISPECIFIC ANTIBODY-DRUG CONJUGATE (ADC) TARGETING TROP2 AND NECTIN4. AK146D1 IS AKESO'S FIRST BISPECIFIC ADC TO ENTER CLINICAL TRIALS.

AKESO'S FIRST BISPECIFIC ADC (TROP2/NECTIN4 ADC) ENTERS CLINICAL TRIALS, STRENGTHENING LEADERSHIP IN 'IO+ADC' 2.0 STRATEGY

LAUSANNE, SWITZERLAND , JULY 1, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE GRANTS OF OPTIONS TO PURCHASE AN AGGREGATE OF 17,000 OF THE COMPANY'S COMMON SHARES TO ONE NEW EMPLOYEE ON JULY 1, 2025 (EACH, A "GRANT"). THE GRANTS WERE OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEES' EMPLOYMENT.

ADC THERAPEUTICS MAKES GRANT TO NEW EMPLOYEE UNDER INDUCEMENT PLAN

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT IT WILL RELEASE ITS SECOND QUARTER 2025 OPERATING RESULTS AFTER THE MARKET CLOSES ON THURSDAY, JULY 31, 2025. A CONFERENCE CALL TO DISCUSS THE COMPANY'S OPERATING RESULTS IS SCHEDULED FOR FRIDAY, AUGUST 1, 2025 AT 9:00 AM ET. INTERESTED PARTIES AND SHAREHOLDERS MAY ACCESS THE CALL VIA TELECONFERENCE OR WEBCAST: TELECONFERENCE: USA TOLL FREE (800) 715-9871  INTERNATIONAL (646) 307-1963 .

AGREE REALTY ANNOUNCES SECOND QUARTER 2025 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION

SAN FRANCISCO AND SUZHOU, CHINA , JUNE 30, 2025 /PRNEWSWIRE/ -- INNOVENT BIOLOGICS, INC. ("INNOVENT") (HKEX: 01801), A WORLD-CLASS BIOPHARMACEUTICAL COMPANY THAT DEVELOPS, MANUFACTURES, AND COMMERCIALIZES HIGH-QUALITY MEDICINES FOR THE TREATMENT OF ONCOLOGY, AUTOIMMUNE, CARDIOVASCULAR AND METABOLIC, OPHTHALMOLOGY, AND OTHER MAJOR DISEASES, HELD ITS ONCOLOGY R&D DAY, UNVEILING ITS FORWARD-LOOKING STRATEGY CENTERED ON DUAL INNOVATION IN NEXT-GENERATION IMMUNO-ONCOLOGY (IO) AND ANTIBODY-DRUG CONJUGATE (ADC) TECHNOLOGIES. THIS STRATEGIC FOCUS AIMS TO REDEFINE THE STANDARDS OF CANCER TREATMENT AND PROPEL INNOVENT TOWARD BECOMING A GLOBAL, PREMIER BIOPHARMACEUTICAL LEADER.

INNOVENT BIOLOGICS SHOWCASES "DUAL INNOVATIONS" AT ONCOLOGY R&D DAY, PIONEERING THE FUTURE OF CANCER TREATMENT WITH NEXT-GENERATION IO AND ADC PLATFORMS

NORWOOD, MASS., JUNE 25, 2025 (GLOBE NEWSWIRE) -- CORBUS PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: CRBP) (CORBUS OR THE COMPANY), A CLINICAL-STAGE COMPANY FOCUSED ON ONCOLOGY AND OBESITY, TODAY ANNOUNCED THE DOSING OF THE FIRST PARTICIPANT IN THE PD-1 COMBINATION ARM OF ITS PHASE 1 STUDY INVESTIGATING CRB-701 IN SOLID TUMORS (THE PHASE 1 WESTERN STUDY). PARTICIPANTS IN THIS ARM OF THE STUDY ARE BEING RANDOMIZED TO THE 2.7 MG/KG AND 3.6 MG/KG COHORTS IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB).

CORBUS PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED WITH ITS NECTIN-4 TARGETING ADC CRB-701 IN COMBINATION WITH PEMBROLIZUMAB

DIFFERENTIATED PH1 PAYLOAD IS A SPLICEOSOME INHIBITOR DESIGNED TO INHIBIT RNA SPLICING, LEADING TO CANCER CELL DEATH AND ACTIVATION OF IMMUNE SYSTEM THROUGH MULTIPLE MECHANISMS

AKARI THERAPEUTICS BOLSTERS GLOBAL IP ESTATE FOR ITS NOVEL ANTIBODY DRUG CONJUGATE (ADC) IMMUNO-ONCOLOGY PAYLOAD, PH1, WITH RECENT GRANTING OF PATENT PROTECTION ACROSS INDIA

Agree Realty

ADC

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC